Category Archives: Patent Eligibility (101)

Board IPR FWD finding Sanofi’s amended claims not unpatentable affirmed

Mylan Laboratories Limited v. Aventis Pharma S.A. Docket No. 2020-1302 (IPR2016-00712) (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/20-1302.RULE_36_JUDGMENT.1-15-2021_1718184.pdf) NEWMAN, O’MALLEY, WALLACH January 15, 2020 Brief Summary:  FC panel affirmed Board IPR FWD finding Sanofi’s amended claims not to be unpatentable for obviousness, public use and section … Continue reading

Posted in Anticipation (35 USC 102), Claim Construction, Inter Parties Review (IPR), IPR, Obviousness, Patent Eligibility (101), Public Use | Leave a comment

DC ineligibility decision erroneous as claims not “solely directed to the printed matter”

C. R. Bard, et al. v. AngioDynamics, Inc. Docket No. 2019-1756, -1934 (http://www.cafc.uscourts.gov/sites/default/files/opinions-orders/19-1756.OPINION.11-10-2020_1683097.pdf) REYNA, SCHALL, STOLL November 10, 2020 Brief Summary:  DC erroneously granted JMOL based on expert mistake and conclusion that printed matter made claims patent ineligible under section … Continue reading

Posted in Inducement to Infringe, Infringement, Patent Eligibility (101), Patentability | Leave a comment

SCOTUS’ 2020 Thryv decision “makes clear that the threshold determination” of CBM review eligibility “non-appealable under 35 U.S.C. 324(e)”

SIPCO, LLC v. Emerson Electric Co. Docket No. 2018-1635 (CBM2016-00095) O’MALLEY, REYNA, CHEN September 25, 2019 Update (11/17/20):  FC panel explained that SCOTUS’ 2020 Thryv decision “makes clear that the threshold determination that SIPCO’s ‘842 patent qualifies for CBM review … Continue reading

Posted in Covered Business Method Reviews, Patent Eligibility (101), Software | Leave a comment

Induced infringement decision reversed (“subjective bad faith”); eligibility decision affirmed (“improving a basic function of a computer”)

TecSec, Inc. v. Adobe Inc., et al. Docket No. 2019-2192, -2258 PROST, REYNA, TARANTO October 23, 2020 Brief Summary:  DC incorrectly excluded evidence of induced infringement (“subjective bad faith”) but correctly found patent eligibility (“directed to improving a basic function … Continue reading

Posted in Inducement to Infringe, Patent Eligibility (101), Section 101 (see also Patentability), Software, Uncategorized | Leave a comment

Revised FC opinion maintains invalidity of one independent claim as claiming a natural law and nothing more but vacates and remands DC invalidity decision regarding second independent claim as including “positioning” limitation”

American Axle & Manufacturing, Inc. v. Neapco Holdings LLC, et al. Docket No. 2018-1763 NEWMAN, TARANTO, STOLL October 3, 2019 (revised July 30, 2020) Update (July 30, 2020): Original FC opinion affirmed the DC decision that AA’s claims are ineligible … Continue reading

Posted in Patent Eligibility (101), Patentability | Leave a comment

DC patent ineligibility holding for Illumina’s fetal DNA-related claims again reversed

Illumina, Inc., Sequenom, Inc. v. Ariosa Diagnostics, Inc. et al. Docket No. 2019-1419 LOURIE, MOORE, REYNA March 17, 2020 Update (August 3, 2020): In a revision of its March 17, 2020 opinion reversing the DC’s 101 ineligibility decision, the FC … Continue reading

Posted in Patent Eligibility (101), Patentability | Leave a comment

Uniloc claim ineligible under § 101 as abstract, claim includes “no specific asserted improvements”

Cisco Systems, Inc. v. Uniloc 2017 LLC Docket No. 2019-2048 MOORE, O’MALLEY, TARANTO May 13, 2020 Non-Precedential Brief Summary: DC finding of patent ineligibility under § 101 affirmed (abstract idea since claim includes “no specific asserted improvements”). Summary: Uniloc appealed … Continue reading

Posted in Patent Eligibility (101), Patentability, Software | Leave a comment

Patent ineligibility decision reversed and remanded as claim is “not rendered ineligible for patent simply because it involves an abstract concept”

Cardionet, LLC et al. v. Infobionic, Inc. Docket No. 2019-1149 DYK, PLAGER, STOLL April 17, 2020 Brief Summary: DC patent ineligibility decision (section 101) reversed and remanded (“not rendered ineligible for patent simply because it involves an abstract concept”). Summary: … Continue reading

Posted in Patent Eligibility (101), Software | Leave a comment

DC patent ineligibility holding for Illumina’s fetal DNA-related claims reversed

Illumina, Inc., Sequenom, Inc. v. Ariosa Diagnostics, Inc. et al. Docket No. 2019-1419 LOURIE, MOORE, REYNA March 17, 2020 Brief Summary: DC finding that Illumina’s fetal DNA-related claims are patent ineligible reversed. Summary: Illumina appealed DC decision finding certain claims … Continue reading

Posted in Patent Eligibility (101), Patentability, Uncategorized | Leave a comment

Board CBM decisions of patent ineligibility affirmed (no improved computer functionality)

Customedia Technologies, LLC v. Dish Network Corp. et al. Docket No. 2018-2239 (CBM2017-00023), 2019-1000 (CBM2017-00032) PROST, DYK, MOORE March 6, 2020 Brief Summary: PTAB CBM decisions of patent ineligibility under 101 affirmed (e.g., “computers are invoked merely as a tool”, … Continue reading

Posted in Patent Eligibility (101), Software | Leave a comment